afternoon, Vice detailed Thank summary David Chief with you, start Dac, Jennifer, second I'm Regulatory ongoing financial Whitaker, overview results, our of Officer; on our questions. Chief to discussion today's and then by our will Grauer, open today provide Officer; development quarter and financial Andreas good call our Borges, by our and Nadia Steve Chief an before Medical more Officer; update Accounting everyone. David we XXXX Clinical Officer; followed our the on Melfi, call Commercial Chief our joined programs. President.
I'll an a Cathy
look at results for our the second quarter. financial let's Now
are of expense the second are costs. to $X.XX quarter, These loss repeated or loan-related foreseeable we incurred October loan a the transaction second of repurchase to cash XXXX in net million million $XX.X million share manufacture expected of related of outlays in R&D or the per $X.XX for and Our loss term of substance $XX narsoplimab of million in quarter per commenced drug In debt XXXX. not was representing to discounted compared $XX.X term that million future. XXXX, share be quarter net $XX.X the of lots total first in $XX.X related the million, a significant $X.X
$XXX.X XXXX, As we of and had on hand. million cash XX, of June investments
amount of value total for term discount off collective a of secured approximately to with Omeros million as The transaction. Healthcare sale to quarter, at $XX.X million remaining by $XXX.X with XX, and $XX.X on carries strengthened and contingent XXXX sales maturing our discretion to loan million in par. and $XXX retired June in in million, This substantially XXXX reasons. our notes, Capital with to to additional transaction highly $XX.X term another with a view by Athyrium notes or million following represents and cash paid value lenders. our out of repurchase XXXX. sheet XX% of a held million OMIDRIA milestones we from transaction $XX.X explained million million by an Highbridge we which representing much and March Athyrium new we payment with In through DRI notional Management, XXXX, outcome to At XXXX. January brings in of in and entered second debt that $XX million with payable notional agreement new more notes $XX.X to had $XXX the calls, our February extended of DRI option value million and X by in exchange maturity our addition, in up reduce the earlier the In favorable XX% for notional loan by cash Management we June, Capital of XXXX royalties outstanding under a Omeros'
In the dates recent into in $XX all manageable as it the each balance XXXX. January Omeros, XXXX
We repurchased down Highbridge,
off was million XXXX financial engineering transaction XX% million completed debt of $XXX.X we ] and nearly the of [ notes, restructuring alone. $XX repurchase both The our outstanding For at par. through extinguished approximately of
the retains
The non-dilutive for lower our to in repurchase is its stock being up this highly than or maturity warrants was additional having to Omeros market. Again, at to from with priced now XXXX extinguished the payments no common prior $XX deal the 'XX profile XX% with further retired outflow extended the new priced on is below competitive, interest our type unusual slightly rate the spend our resulting or February Omeros than XXXX. and term to on the derisked debt majority market, the sheet notes. the XX% of June We've principal included. a transaction typical notes. interest rather loan above So outstanding balance premium prevailing transaction, the million to of also for ability cash XXXX
also remaining term delayed the addition, draw I better to of the to than fund notes lenders request, X, commitment other commitment those and/or includes development lenders received mentioned In to capital fuel early to $XX commercialization terms cash total to narsoplimab's the in This million million $XX FDA of earlier, notional allow that given with Omeros contingent value, of XXXX loan. transaction preserving by on TA-TMA. source has outstanding the narsoplimab our outstanding provided our additional to loan program provides fund Athyrium they an approval on our July to reduce term while of no facility additional agreement reduce Omeros balance option to as of at prior Highbridge. a join an additional to are
The balance XXXX, a and a a bit by our the ready
notes our development programs. the fund
Building of early million the outstanding balance recent at term those manage value-driving a exchange. continue Collectively, transaction,
In open potential of of XXXX to Athyrium outstanding out notes, amount exchange our reduces debt of to Highbridge value more this half with portion our earlier stock, remove to maturing the and our overhang. flexibility of principal replacing by of our that of discount with maturing our and within advancing non-dilutively, shareholder remaining a summary, repurchase in the retired future than treasury the XXXX of $X.X and calls the debt value. of upcoming substantial lesser outstanding date our return also this on value funding narsoplimab X% in transaction our capital notional recent par and value, loan through of in all catalysts [ retain another common commercialization substantial associated cap to XXXX structure market and represent ] retirement represents Omeros' substantial and a our XXXX and these part of notes to As provides purchases repurchase calls XXXX also cap to all managing step financial debt we including with June
that, update I'll our inhibitor, an targeting with to pathway move complement. development MASP-X narsoplimab, let's on our Now of lectin programs. on begin with the
last Application, narsoplimab our at in we stem transplant-associated or and Shareholder continue As for earnings call of June, cell I our our engage BLA, microangiopathy with to Biologics resubmission Meeting proposed described Annual in the License FDA in thrombotic regarding TA-TMA. hematopoietic or
development upcoming FDA FDA. with serve of diseases often The particularly we're for hub on FDA's and meeting BLA conditions a encouraged history variable development natural Another the support therapies not the within rare scheduled for point is for connection is the resubmission. single fully rare is designed which of and will these for the innovation the by promote focus challenging. and as further In been to recognizing the has engagement hub, recent We're therapeutics to preparing rare of which meantime, diseases. of that disease establishment especially understood,
with authored available. for becomes information resubmission provide in one
Also, to our from the interactions the external survival already access and of international TA-TMA we trial program. data by a pivotal second are continue increasingly plans to TA-TMA. access timing, their detailing when for narsoplimab a more directed Regarding experts our the between anticipated under in our survival and available, our publications results in FDA more a definitive the Physicians to transplant its manuscripts will further and rigorous X expanded update request control preparation, comparison expanded addition patients
the Given FDA what recently these approval rapidly to nonproprietary condition, we zaltenibart. MASP-X program with pathway do targeting alternative
OMSXXX, MASP-X this continue our we for for lead inhibitor parallel development we our to adopted In treatment efforts narsoplimab, of for continue antibody name, complement. life-threatening a has no clinical advancing that our the there now obtain to can is help patients. approved
CX have ongoing ongoing annual rare phase zaltenibart complementary X disorder hematologic a life-threatening Association or disease a studies Hematology PNH inhibitor, with European in PNH, We'll trial. June, or II our debilitating zaltenibart Dr. The disease. in clinical We the stage and in Griffin, PNH The life-threatening Hospital University dose evaluated treatment CXG, recognized of Congress first to study in hemoglobinuria of kidney indications: a multiple St. adjunctive the phase from II response at James potentially PNH paroxysmal glomerulopathy nocturnal and look the study of patients an the switchover presented levels. with internationally suboptimal treatment U.K., our results X expert ravulizumab. Morag
As in to zaltenibart previously adequately treatment those study patients combination and to responding adjunctive then patients discussed, zaltenibart while switched treatment receiving were began this monotherapy. ravulizumab
improvement therapy consistent providing remains on study. drug scheduled annual look with and XX demonstrated presentation well of XX was as profiles our X.XX last stage was year. data completing entering monotherapy prevention in later their improvements been of switchover you the hemoglobin these extension in results is of to at submitted During the improvement study well and of in the also for patients patient mean meaningful efficacy deciliter with with abstract sharing [indiscernible] December. zaltenibart significant these the the long-term statistically meeting from tolerated. hemoglobin of extravascular has absolute reticulocyte monotherapy. sustained are levels We Society visit to experience the and safe as October, hemolysis. monotherapy zaltenibart safety clinical intravascular Hematology and of for clinically statistically
The demonstration study reticulocyte to and including zaltenibart strong, American The our per this counts In baseline significant forward advanced and as and adjunctive grams period, patients Absolute count
Our from phase clinical derived complement of analysis is American and together data inhibit breakthrough from second dose now completed inhibitor presentation finalize in identify treatment, subcutaneous of meaning December, selecting complement the who phase our zaltenibart III ongoing III Society level After data of our study our I and MASP-X of switchover and selection required phase study have the amended continues the XXXX dose be received the zaltenibart needed upcoming our inhibition treatment concentrations study at they the phase we meeting basis data, II provides to protocol
We to patients healthy PNH subjects progress These will plasma naive to the for early trials. This one hemolysis. last to not soon. for therapy. previous well. are have with studies results to the the that in Hematology PNH
track on trials required naive remain initiate we program, progressing as switch later over year. or III this both and phase been phase our completed PNH either to have planned. III our to ahead Looking patients are All activities
international they zaltenibart on We protocols and to Physician with MASP-X competitors. and advisory to and X demonstrate that efficient U.S. uptake. are us prepare potential PNH that data, for us the current ensure advisers to and its have medical are well community working as see and
These our positively properties future execution. the to the significant have both zaltenibart group will study against of gather when to zaltenibart's PNH target help study input needs uniformly to and boards and closely best for experts responded how zaltenibart of understand as approved, success our completed clinical position patients designed to expect to unique focus
been and III our already Phase prepared the with plan all
With and diverse team clinical We Our European for trial the our enrollment. and been manufactured developing which site trials. external operations that designs. strong earmarked has awarded, anticipate having and and our investigators, participation alignment briefing and vendors needed regulatory we identification will respect to to manufacturing already efforts, confirm been have regulatory utilization. speed geographically identified support Phase zaltenibart front, has III on for site zaltenibart with program begun broad serve both should adoption post-approval clinical and and already to FDA relationships have clinical our materials All has
pre-Phase Following scheduled requested. III incorporated all our earlier have year, and and with already meeting FDA we regulators, with look both which feedback, been FDA U.S. forward our upcoming or this meetings European we to
or in zaltenibart Turning now to CXG. glomerulopathy CX
program in sharing Our study Phase early The this planned to later first to year quarter look data forward study We next. of from III is II XXXX. in the enrolling. or this Phase is CXG initiate
wide completion, our we drive while alternative applicability initiate objective Finally, on of to successful pathway Phase primary quickly PNH our remain current III focused is MASP-X zaltenibart the inhibition. to acutely and them trials to and
have array targeting competitors pathway IgA derisked discussed, indications include previously agents zaltenibart CX age-related nephropathy, PNH. As with and for These macular alternative glomerulopathy degeneration. beyond of an substantially other the
and these currently lectin and you better pathway available consistent patient dosing compliance. to our over more the zaltenibart now OMSXXXX. turn of significant All benefits efficacy could convenience franchise specifically on provide
I'll others, back update and superior and treatments, safety,
long-acting Phase either identified. support inhibitor now I the The MASP-X. completed intravenously. once dose single quarterly or subcutaneously next-generation, ascending of dosing, OMSXXXX. successfully safety and tolerated well remains results multiple Our We've no administered studies of OMSXXXX concerns with both
AMD. value model As of report, Wet macular primate previously receiving OMSXXXX, later this these of for major in OMSXXXX recent indications degeneration, disclosed, holds study quarter. preclinical showed AMD, development look we also In large forward data Eylea, inhibition by one efficacy. known being as good Wet the MASP-X a now we're running neovascular share which comparing evaluating several We potential revenue chronic a to murine AMD. those of age-related to But are
regarded the As be produced painful only both chamber currently all By eyes work because all by intravitreal very alternative. does directly to a meaning or require orally. to and AMD last the our Wet liver, frequent is patients effective Lucentis, into that be the by throughout of injections posterior injections, their any administration, administration through attractive their would is MASP-X discussed Eylea, eye. in require approved body the be on is systemic an therapeutic achieved indicates and our that that route AMD, MASP-X physicians a not subcutaneous they it contrast, in inhibition intravenously, large date as call, receive whether patients for injections highly of Wet market, treatments
MASP-X As earlier [indiscernible] as work earnings including acute or continue last the concerning ARDS, and detailed both severe we HXNX and inhibition the respiratory and COVID with Annual during as narsoplimab June, HXNX. in and Meeting our or in an calls acute long our recently distress well Shareholder
In utilization the of would physicians indications. broad therapeutic and addition early a diagnostic MASP-X these also of Adoption utilization inhibitor and also drive and diagnostic and hyperactivation pathway but adoption not their of in would potential across wide members diseases. lectin and developing MASP-X for diagnosis, to inhibition, MASP-X a help therapeutic only our narsoplimab these patients approach of for franchise we're other
on important become efforts As share updates available, our we'll they further on this front.
complement MASP-X and zaltenibart from orally MASP-X learned In development are levered and applied lessons OMSXXXX, agents. includes available addition antibodies and orally programs. franchise MASP-X being to growing small small MASP-X progressing of molecule our advancing our rapidly narsoplimab, programs molecule our inhibitor MASP-X for program and with MASP-X our administered Both to these
inhibitor OMSXXX, compulsions Let's treating addictions, and our turn to PDEX now disorders. aimed program movement at
for Abuse As that shift or need treatment a to for disorder. addiction previously urgent National cocaine from on we the Drug unmet our for disclosed, NIDA, Institute focus requested and OMSXXX use nicotine the
anticipate receiving cocaine million NIDA preclinical of study funded OMSXXX. We to primates grant. toxicology program exposed results and year $X.X from a Our later concurrently by a is through this
the plan together treatment Assuming double-blind toxicology we to study, individuals cocaine next year with in evaluating inpatient randomized positive clinical a disorder. NIDA, in use with OMSXXX initiate trial results
liquid immunomodulators There the discussed and also the by most result, levodopa, or levodopa-induced movement potential a major of treatment function vaccines; disease our therapeutic. OMSXXX therapy our also family certainly but used in immunomodulators, is to generating amenable or in platforms vivo earlier large platforms, treatment our target cellular exciting data, and effective attack calls, able LID, biologic disease. a and CAR-T, compelling time-intensive that continue Around and discussion to dosing. treat with exploring therapeutic as these patients our of This only for stream disorders, cancer applicability, is platforms cancer program strengthening in antigen-driven and cellular for As intellectual of
We'll and modification we're steady two, to need immuno-oncology our broad designed immune to and really essentially good an Each possibly oncotoxins and Parkinson's quickly. our cancer up is property Parkinson's and future problem that therapeutics, levels cancer surface IO cell sustainably, eliminate not memory LID tumors signaling All LID. of as against positions. market a our caused four, each are their for for CDX specifically one, in multiply a use advancing wrap in expanding driven dyskinesias CDX, cell namely no cancer untapped both and safe targets represents adoptive the and as to: supersede novel cell common commercial with no T T approaches and could and respective engineering intracellular both engineering. repetitive and requires cells effectively increase create three, memory solid and and represent relapse, we
data one volume in working are the to now growing Chief applications call we results. a public include the and Given David data, Officer, detailed initial [ over through Accounting patent ], will avenues. we our through go or more been have applications. discussion of fund Once breadth our of share all our patent diligently more turn
I'll encouraging to Borges, to them financial
